HCV刺激小鼠小胶质细胞后TLR9 mRNA的表达  

Expression of TLR9 mRNA in BV2 cells after HCV stimulation

作　　者：王振海[1] 李晓梅 胡坤[3] 

机构地区：[1]宁夏医科大学附属总医院神经内科,宁夏颅脑疾病重点实验室-省部共建国家级重点实验室培育基地,750004 [2]宁夏红寺堡区人民医院内科,751900 [3]宁夏医科大学附属总医院综合科,750004

出　　处：《中国神经免疫学和神经病学杂志》2011年第6期407-410,共4页Chinese Journal of Neuroimmunology and Neurology

基　　金：2011年国家自然科学基金面上项目(编号:81160151);宁夏医科大学“博士学位建设学科”开放课题(编号:KF2010-34)

摘　　要：目的检测丙型肝炎病毒(HCV)刺激小鼠小胶质细胞(BV2)后Toll样受体9(TLR9)的表达,探讨TLR9参与小胶质细胞抗HCV的免疫发病机制。方法将BV2细胞分为HCV阳性血清组(以含20% HCV阳性血清的DMEM培养),健康人血清组(以含20%健康人血清的DMEM培养),空白对照组(以含10%胎牛血清的DMEM培养),分别在培养4、12、20、36h收集细胞,以实时荧光定量聚合酶链反应(RT-qPCR)法观察TLR9 mRNA表达。结果 BV2细胞有TLR9 mRNA表达。HCV阳性血清组中TLR9 mRNA于4、12、20、36h各时间点相对表达量分别为3.50±0.33、2.03±0.10、2.05±0.12、2.02±0.14,均高于健康人血清对照组(分别为0.99±0.08、1.01±0.09、1.00±0.10、0.99±0.09)和空白对照组(均为1)(P<0.01),且以HCV阳性血清刺激4h后TLR9 mRNA表达量最高(P<0.01)。结论 BV2细胞能够表达TLR9 mRNA,且BV2经HCV刺激后TLR9 mRNA表达明显增加,提示TLR9可能参与BV2抗HCV的免疫发病机制。Objective To detected the expression of TLR9 after mouse microglia （BV2） were stimulated by hepatitis C virus （HCV）, so as to explore the immune mechanisms against HCV through TI,R9 in microglia. Methods BV2 cells were divided into 3 groups： HCV-positive serum group, normal serum group and blank control group. BV2 cells were collected at 4, 12, 20, 36 hours after cultivation, and then the expression of TLR9 mRNA was detected on different times by real-time quantitative PCR （RT qPCR）. Results There was TI,R9 mRNA expression in BV2 cells. The expression of TLR9 mRNA in HCV-positive serum group at different time was 3.50±0.33, 2.03±0.10, 2.05±0. 12, 2.02±0.14, respectively; they were higher than those in normal serum group （0.99±0.08, 1.01±0.09, 1.00±0. 10, 0.99±0.09） and blank control group （all in 1） （P〈0.01） ; and in HCV-positive serum group the expression of TLR9 mRNA was the highest at 4h （P〈0.01）. Conclusions BV2 cells could express TLR9 mRNA, and the expression of TI,R9 was significantly increased after HCV stimulation, TLR9 might be involved in immune process of BV2 against HCV.

关 键 词：小胶质细胞 肝炎病毒属 TOLL样受体9 实时荧光定量PCR 

分 类 号：R512.6[医药卫生—内科学]